Company: BLLN
Filing Date: 2025-09-17
Form Type: DRS/A
Source: 0001193125-25-206347
Chunk: 345

Company: BillionToOne, Inc.
Filing Date: 2025-09-17
Form: DRS/A
Chunk 345
---
 related testing services, and whether achievement of the milestones and testing services are dependent on parties other than the Company. The Company recognizes
revenue for the single performance obligation over time as the related services are provided. The Company utilizes an input method to measure progress to depict the transfer of services as the Company believes it provides a faithful depiction of the
transfer of services over the contract. In accordance with ASC 606, the Company applies the constraint on variable consideration and includes such amounts in the transaction price only to the extent that it is probable that a significant reversal of
cumulative revenue will not occur when the associated uncertainty is resolved.

As of December 31, 2024, the Company’s further performance
obligations beyond one year were $6.3 million. The Company expects to recognize substantially all of the remaining performance obligations as revenue over the 12 months following December 31, 2024.

F-13

B ILLIONT OO NE, INC. Notes to Financial Statements Disaggregation of revenue The following table presents disaggregation of revenue by Oncology, Prenatal and Clinical trial support services:

|                                 |     | Year ended    
 December 31,  |   2023 |     |   |    2024 |
|:--------------------------------|:----|:--------------|-------:|:----|:--|--------:|
|                                 |     | -in thousands |        |     |   |         |
| Prenatal                        |     | $             | 68,803 |     | $ | 145,901 |
| Oncology                        |     |               |      - |     |   |   2,944 |
| Clinical trial support services |     |               |  2,926 |     |   |   3,737 |
| Total revenues                  |     | $             | 71,729 |     | $ | 152,582 |

Substantially all revenues recognized for the years ended December 31, 2023 and 2024 was generated in the United States. Deferred revenue Deferred revenue, which is a contract liability, consists of billings or cash received for services in advance of revenue recognition and is recognized as revenue when all the Company’s revenue recognition criteria are met. As of December 31, 2023 and 2024, the deferred revenue balance was $3.0 million and $2.8 million, respectively, all of which is considered short-term. For the years ended December 31, 2023